Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees

Journal of Experimental Medicine

Volumn 179, Issue 4, 1994, Pages 1253-1259

  Van Der Poll, Tom ^a   Levi, Marcel ^a,d   Hack, C Erik ^b   Ten Cate, Hugo ^a   Van Deventer, Sander J H ^a   Eerenberg, Anke J M ^b   De Groot, Els R ^b   Jansen, Jaap ^a   Gallati, Harald ^c   Büller, Harry R ^a   Ten Cate, Jan W ^a   Aarden, Lucien A ^b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b CENTRAL LABORATORY   (Netherlands)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; ESCHERICHIA COLI ENDOTOXIN; INTERLEUKIN 6;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CLOTTING; CHIMPANZEE; CONTROLLED STUDY; DEGRANULATION; DOSE RESPONSE; ENDOTOXEMIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBRINOLYSIS; LEUKOCYTOSIS; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

EID: 0028323245     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.179.4.1253     Document Type: Article

References (38)

1. Le, J., and J. Vilcek. 1989. Interleukin 6: a multifunctional cytokine regulating immune reactions and the acute phase protein sequence. Lab. Invest. 61:588.
2. Fong, Y., K.J. Tracey, L.L. Moldawer, D.G. Hesse, K.R. Manogue, J.S. Kenney, A.T. Lee, G.C. Kuo, A.C. Allison, S.F. Lowry, and A. Cerami. 1989. Antibodies to cachectin/tumor necrosis factor reduce interleukin 1β and interleukin 6 appearance during lethal bacteremia. J. Exp. Med. 170:1627.
3. Hack, C.E., E.R. de Groot, R.J.F. Felt-Bersma, J.H. Nuijens, R.J.M. Strack van Schijndel, A.J.M. Eerenberg-Belmer, L.G. Thijs, and L.A. Aarden. 1989. Increased plasma levels of interleukin-6 in sepsis. Blood. 74:1704.
4. Waage, A., P. Brandtzaeg, A. Halstensen, P. Kierulf, and T. Espevik. 1989. The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome. J. Exp. Med. 169:333.
5. Heremans, H., C. Dillen, W. Put, J. van Damme, and A. Billiau. 1992. Protective effect of anti-interleukin (IL)-6 antibody against endotoxin, associated with paradoxically increased IL-6 levels. Eur. J. Immunol. 22:2395.
6. Libert, C., A. Vink, P. Coulie, P. Brouckaert, B. Everaerdt, J. van Snick, and W. Fiers. 1992. Limited involvement of interleukin-6 in the pathogenesis of lethal septic shock as revealed by the effect of monoclonal antibodies against interleukin-6 or its receptor in various murine models. Eur. J. Immunol. 22:2625.
7. Preiser, J.-C., D. Schmartz, P. van der Linden, J. Content, P. vanden Bussche, W. Buurman, W. Sebald, E. Dupont, M.R. Pinsky, and J.-L. Vincent. 1991. Interleukin-6 administration has no acute hemodynamic or hematologic effect in the dog. Cytokine. 3:1.
8. Aderka, D., J. Le, and J. Vilcek. 1989. IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells and mice. J. Immunol. 143:3517.
9. Schindler, R., J. Mancilla, S. Endres, R. Ghorbani, S.C. Clark, and C.A. Dinarello. 1990. Correlations and interactions in the production of interleukin-6 (IL-6), IL-1 and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. Blood. 75:40.
10. Brakenhoff, J.P.J., M. Hart, E.R. de Groot, F. di Padova, and L. A. Aarden. 1990. Structure-function analysis of human IL-6. Epitope mapping of neutralizing monoclonal antibodies with amino- and carboxyl-terminal deletion mutants. J. Immunol. 145:561.
11. Van Leenen, D., T. van der Poll, M. Levi, H. ten Cate, S.J.H. van Deventer, C.E. Hack, L.A. Aarden, and J.W. ten Cate. 1993. Pentoxifylline attenuates neutrophil activation in experimental endotoxins in chimpanzees. J. Immunol. 151:2318.
12. Helle, M., L. Boeije, E.R. de Groot, A. de Vos, and L.A. Aarden. 1991. Sensitive ELISA for interleukin-6. Detection of IL-6 in biological fluids: synovial fluids and sera. J. Immunol. Methods. 138:47.
13. Helle, M., L. Boeije, and L.A. Aarden. 1988. Functional discrimination between interleukin 6 and interleukin 1. Eur. J. Immunol. 18:1535.
14. Aarden, L.A. 1991. Plasmacytomas. In Mechanisms of B cell neoplasia 1991. F. Melchers and M. Potter, editors. Roche, Basel, Switzerland, 429.
15. Van der Poll, T., J. Jansen, D. van Leenen, M. von der Möhlen, M. Levi, H. ten Cate, H. Gallati, J.W. ten Cate, and S.J.H. van Deventer. 1993. Release of soluble receptors for tumor necrosis factor in clinical sepsis and experimental endotoxemia. J. Infect. Dis. 158:455.
16. Girardin, E., P. Roux-Lombard, G.E. Grau, P. Suter, H. Gallati, the J5 study group, and J.-M. Dayer. 1992. Imbalance between tumour necrosis factor-alpha and soluble TNF receptor concentrations in severe meningococcaemia. Immunology. 76:20.
17. Hack, C.E., M. Hart, R.J.M. Strack van Schijndel, A.J.M. Eerenberg, J.H. Nuijens, L.G. Thijs, and L.A. Aarden. 1992. Interleukin-8 in sepsis: relation to shock and inflammatory mediators. Infect. Immun. 60:2835.
18. 1-antitrypsin and lactoferrin in sepsis: evidence for neutrophils as mediators of fatal sepsis. J. Lab. Clin. Med. 119:159.
19. Levi, M., C.E. Hack, J.P. de Boer, D.P.M. Brandjes, H.R. Büller, and J.W. ten Cate. 1991. Reduction of contact activation related fibrinolytic activity in factor XII deficient patients: further evidence for the role of the contact system in fibrinolysis in vivo. J. Clin. Invest. 88:1155.
20. Thompson, J.M., M.J.R. Gralow, R. Levy, R.A. Miller. 1985. The optimal application of forward and ninety-degree light scatter in flow cytometry for the gating of mononuclear cells. Cytometry. 6:401.
21. Lu, Z.Y., J. Brochier, J. Wijdenes, H. Brailly, R. Bataille, and B. Klein. 1992. High amounts of circulating interleukin (IL)-6 in the form of monomeric immune complexes during anti-IL-6 therapy. Towards a new methodology for measuring overall cytokine production in human in vivo. Eur. J. Immunol. 22:2819.
22. Van Bladel, S., C. Libert, and W. Fiers. 1991. Interleukin-6 enhances the expression of tumor necrosis factor receptors on hepatoma cells and hepatocytes. Cytokine. 3:149.
23. Cairns, J.A., G.R. Guy, and Y.H. Tan. 1992. Interleukin-6 regulates the cytotoxic effects of tumour necrosis factor on U937 cells. Immunology. 75:669.
24. Fernandez-Botran, R. 1991. Soluble cytokine receptors: their role in immunoregulation. FASEB (Fed. Am. Soc. Exp. Biol.) J. 5:2567.
25. Van Zee, K.J., T. Kohno, E. Fischer, C.S. Rock, L.L. Moldawer, and S.F. Lowry. 1992. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor α in vitro and in vivo. Proc. Natl. Acad. Sci. USA. 89:4845.
26. Ulich, T.R., J. del Castillo, and K. Guo. 1989. In vivo hematogic effects of recombinant interleukin-6 on hematopoiesis and circulating numbers of RBCs and WBCs. Blood. 73:108.
27. Van der Poll, T., S.J.H. van Deventer, C.E. Hack, G.J. Wolbink, L.A. Aarden, H.R. Büller, and J.W. ten Cate. 1992. Effects on leukocytes following injection of tumor necrosis factor into healthy humans. Blood. 79:693.
28. Van Zee, K.J., E. Fisher, A.S. Hawes, E.A. Hébert, T.G. Terrel, J.B. Baker, S.F. Lowry, and L.L. Moldawer. 1992. Effects of intravenous IL-8 administration in nonhuman primates. J. Immunol. 148:1746.
29. Van Deventer, S.J.H., C.E. Hack, G.J. Wolbink, H.J. Voermans, R.J.M. Strack van Schijndel, J.W. ten Cate, and L.G. Thijs. 1991. Endotoxin-induced neutrophil activation. The role of complement revisited. Prog. Clin. Biol. Res. 367:101.
30. Borish, L., R. Rosenbaum, L. Albury, and S. Clark. 1989. Activation of neutrophils by interleukin-6. Cell Immunol. 121:280.
31. Baggiolini, M., A. Waltz, and S.L. Kunkel. 1989. Neutrophil-activating peptide-1/interleukin-8, a novel cytokine that activates neutrophils. J. Clin. Invest. 84:1045.
32. Yuo, A., S. Kitagawa, T. Kasahara, K. Matsushima, M. Saito, and F. Takaku. 1991. Stimulation and priming of human neutrophils by interleukin-8: cooperation with tumor necrosis factor and colony-stimulating factors. Blood. 78:2708.
33. Van Deventer, S.J.H.. H.R. Büller, J.W. ten Cate, L.A. Aarden, C.E. Hack, and A. Sturk. 1990. Experimental endotoxemia humans. Analysis of cytokine release and coagulation, fibrinolytic and complement pathways. Blood. 76:2520.
34. Levi, M., H. ten Cate, T. van der Poll, and S.J.H. van Deventer. 1993. New insights in the pathogenesis of disseminated intravascular coagulation in sepsis. JAMA (J. Am. Med. Assoc.). 270:975.
35. Levi, M., H. ten Cate, K.A. Bauer, T. van der Poll, T.S. Edgington, H.R. Büller, S.J.H. van Deventer, C.E. Hack, J.W. ten Gate, and R.D. Rosenberg. 1994. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J. Clin. Invest. 93:114.
36. Cermak, J., N.S. Key, R.R. Bach, J. Balla, H.S. Jacob, and G.M. Vercelotti. 1993. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood. 82:513.
37. Creasey, A.A., A.C.K. Chang, L. Feigen, T.C. Wun, F.B. Taylor, Jr., and L.B. Hinshaw. 1993. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J. Clin. Invest. 91:2850.
38. Van der Poll, T., M. Levi, S.J.H. van Deventer, H. ten Cate, B. Haagmans, B.J. Biemond, H.R. Büller, C.E. Hack, and J.W. ten Cate. 1994. Differential effects of anti-tumor necrosis factor monoclonal antibodies on systemic inflammatory responses in experimental endotoxemia in chimpanzees. Blood. 83:446.